Clinical Trials
7 trialsNCT03496766 2025-03-05
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Spanish Lung Cancer Group
Phase 2 Terminated
NCT05693090 2023-03-06
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Kura Oncology, Inc.
Phase 1 Withdrawn
NCT00025480 2019-03-13
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00055757 2013-06-04
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005842 2013-02-11
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005041 2012-11-09
R115777 in Treating Patients With Relapsed Small Cell Lung Cancer
NYU Langone Health
Phase 2 Completed
NCT00005989 2011-08-04
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Mayo Clinic
Phase 2 Completed